NCT05037045Completed
Effect of Gene Polymorphisms on GLP-1 Receptor Agonists Response in Patients With T2DM
Department of Pharmacy, the Affiliated Hospital of Xuzhou Medical University
Source: ClinicalTrials.gov · Last updated 12 Nov 2024
Brief summary (registry, in English)
1. This is an prospective study to evaluate the effect of gene polymorphisms on therapeutic responses to glucagon like peptide-1 receptor agonist (GLP-1 RA) in patients with T2DM. 2. T2DM patients and healthy subjects were recruited to identify genotypes and detect the level of T2DM susceptibility genes expression levels in the plasma of healthy participants and T2DM patients. 3. This is a retrospective cohort study of patients with T2DM who were treated with exenatide twice daily as a part of their diabetes care for at least 12 months.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 338 (actual)
- First submitted
- 27 Aug 2021
- Start date
- Jan 2019
- Primary completion date
- Oct 2023
- Lead sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Diseases
- Type 2 diabetes
- NCT number
- NCT05037045
What you commit to
- Study type: Interventional
- Participants enrolled: 338
- From Jan 2019 to the primary completion date, Oct 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- patients receiving GLP-1 analogues, weight loss drugs, glucocorticoids, drugs affecting gastrointestinal peristalsis in the past 3 months；
- those with missing data at the time points of baseline, 3 months, and 6 months after GLP-1 RA therapy.
Other illness
- Patients with serious diseases such as acute myocardial infarction, cerebral vascular accident, trauma, kidney or liver diseases, severe gastrointestinal dysfunction, and history of pancreatitis；
Who the study is looking for
- a diagnosis of T2DM；
- a body mass index (BMI) of 20-35 kg/m2；
- an HbA1c of 7.0%-12%, an age of 25-70 years；
- required data available at baseline, 3 months, and 6 months after GLP-1 RA therapy.
Age in the registry: 25 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Endocrinology Coordinator of this site? Confirm its status | Xuzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.